TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.
TMRW is a life sciences technology company setting new standards for transparency, safety, and accountability in IVF and cell management. TMRW's platform, the world's first automated cryo-management for eggs and embryos, provides a complete digital chain of custody fully integrated with a robotic storage and monitoring solution. This is in contrast to the manual and analog methods that have gone unchanged throughout the history of IVF. With TMRW's platform, clinics significantly reduce the chances of potentially devastating errors. The TMRW team includes celebrated innovators in fertility, embryology, cryo-management, automation, software development, and robotics. TMRW is founded by Joshua Abram, Alan Murray, and Dr. Jeffrey Port in 2018 and is based in New York, New York.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 1, 2022 | Funding Round | — | 1 | Amy Schumer | — | Detail |
Jul 21, 2021 | Debt Financing | — | — | — | — | Detail |
Jul 20, 2021 | Series C | $105M | 10 | Transformation Capital | — | Detail |
Dec 17, 2019 | Series B | $36.50M | 1 | 5AM Ventures | — | Detail |
May 29, 2019 | Series A | $12M | 1 | Special Situations Life Sciences Innovation Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Amy Schumer | Yes | Funding Round |
Transformation Capital | Yes | Series C |
5AM Ventures | — | Series C |
Anne Wojcicki | — | Series C |
Casdin Capital | — | Series C |
GV | — | Series C |
Peter Thiel | — | Series C |
Presight Capital | — | Series C |
Special Situations Life Sciences Innovation Fund | — | Series C |
Susan Wojcicki | — | Series C |